Dr. Reddy's Laboratories Limited (NSE:DRREDDY)

Dr. Reddy's Laboratories Ratios and Metrics

Market cap in millions INR. Fiscal year is April - March.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul 15, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Market Capitalization	1,049,441	953,168	1,024,969	767,655	714,500	749,317
Market Cap Growth	-7.00%	-7.00%	33.52%	7.44%	-4.65%	45.01%
Enterprise Value	1,042,077	948,175	972,270	736,818	707,464	753,909
Last Close Price	1260.90	1136.99	1216.61	906.23	836.33	875.25
PE Ratio	18.56	16.86	18.41	17.03	30.32	43.47
PS Ratio	3.22	2.93	3.67	3.12	3.33	3.95
PB Ratio	3.11	2.83	3.65	3.32	3.75	4.33
P/TBV Ratio	4.67	4.24	4.28	3.92	4.50	5.64
P/FCF Ratio	55.46	50.37	35.31	16.14	53.13	28.86
P/OCF Ratio	22.60	20.53	22.56	13.04	25.42	20.99
EV/Sales Ratio	3.20	2.91	3.48	3.00	3.30	3.97
EV/EBITDA Ratio	11.54	10.67	12.26	11.16	14.82	16.50
EV/EBIT Ratio	14.23	12.98	14.82	13.79	19.70	22.91
EV/FCF Ratio	55.07	50.10	33.49	15.50	52.61	29.04
Debt / Equity Ratio	0.14	0.14	0.07	0.06	0.18	0.18
Debt / EBITDA Ratio	0.52	0.52	0.25	0.20	0.71	0.66
Debt / FCF Ratio	2.47	2.47	0.69	0.28	2.52	1.17
Asset Turnover	0.74	0.74	0.79	0.80	0.77	0.76
Inventory Turnover	2.01	2.01	2.06	2.14	2.09	2.15
Quick Ratio	1.16	1.16	1.72	1.58	1.24	1.07
Current Ratio	1.92	1.92	2.58	2.38	1.93	1.78
Return on Equity (ROE)	18.53%	18.53%	21.77%	21.38%	12.96%	10.51%
Return on Assets (ROA)	10.37%	10.37%	11.56%	10.86%	8.04%	8.27%
Return on Capital (ROIC)	13.34%	13.34%	15.04%	14.24%	10.50%	10.81%
Return on Capital Employed (ROCE)	20.10%	20.10%	22.50%	22.60%	18.10%	18.10%
Earnings Yield	5.39%	5.93%	5.43%	5.87%	3.30%	2.30%
FCF Yield	1.80%	1.98%	2.83%	6.19%	1.88%	3.46%
Dividend Yield	0.64%	0.70%	0.66%	0.88%	0.72%	0.57%
Payout Ratio	11.78%	11.78%	11.94%	11.05%	17.59%	24.06%
Buyback Yield / Dilution	-0.08%	-0.08%	-0.19%	-0.03%	-0.01%	-0.14%
Total Shareholder Return	0.56%	0.63%	0.47%	0.85%	0.70%	0.43%

Updated Jan 23, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.